The first evidence that inhibiting IDO could be utilized as a therapeutic modality against tumors came in 2002, when Friberg et al. (2002) showed that mice bearing Lewis lung carcinoma and administered 1-MT demonstrated slower tumor growth, when compared to mice not administered the IDO inhibitor. Here, IDO1 is linked to neoplasm.